Selonabant

Last updated

Selonabant
Selonabant.svg
Clinical data
Other namesANEB-001; ANEB001; V-24343; V24343
Drug class Cannabinoid receptor antagonist; Cannabinoid CB1 receptor antagonist; Cannabinoid antidote
Identifiers
  • N-tert-butyl-3-[(R)-(4-chlorophenyl)-[2-(trifluoromethyl)phenyl]methoxy]azetidine-1-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C22H24ClF3N2O2
Molar mass 440.89 g·mol−1
3D model (JSmol)
  • CC(C)(C)NC(=O)N1CC(C1)O[C@H](C2=CC=C(C=C2)Cl)C3=CC=CC=C3C(F)(F)F
  • InChI=1S/C22H24ClF3N2O2/c1-21(2,3)27-20(29)28-12-16(13-28)30-19(14-8-10-15(23)11-9-14)17-6-4-5-7-18(17)22(24,25)26/h4-11,16,19H,12-13H2,1-3H3,(H,27,29)/t19-/m1/s1
  • Key:BNLYOVHLLDBOFZ-LJQANCHMSA-N

Selonabant (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code names ANEB-001, V-24343) is a cannabinoid CB1 receptor antagonist which is under development for the treatment of acute cannabinoid intoxication. [1] [2] [3] It was also previously being developed to treat obesity, but development for this indication was discontinued. [1] The drug is administered by intravenous infusion. [1] It dramatically reduced the subjective effects of Δ9-tetrahydrocannabinol (THC) in a clinical trial. [3] Selonabant is being developed by Vernalis and Anebulo Pharmaceuticals. [1] [2] As of December 2024, it is in phase 2 trials. [1] [2]

See also

References

  1. 1 2 3 4 5 "Anebulo Pharmaceuticals". AdisInsight. 26 December 2024. Retrieved 25 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on Selonabant with Synapse". Synapse. 23 January 2025. Retrieved 25 February 2025.
  3. 1 2 Gorbenko AA, Heuberger JA, Juachon M, Klaassen E, Tagen M, Lawler JF, et al. (February 2025). "CB1 Receptor Antagonist Selonabant (ANEB-001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial". Clinical Pharmacology and Therapeutics. 117 (5): 1427–1436. doi: 10.1002/cpt.3581 . PMC   11993283 . PMID   39898464.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.